Satavaptan
As of the edition of 20 October 2026, Satavaptan is a small molecule: stopped in 2008; acts on AVPR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2008
- Kind
- Small molecule
- Registered trials
- 11, 3 stopped early
- Disease areas
- Digestive system; Nutrition and metabolism; Hormones; Nervous system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AVPR2 | Vasopressin V2 receptor | P30518 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 7 | 4 | 0 | 3 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2001 to now |